Large scale expansion of Vγ9Vδ2 T lymphocytes from human peripheral blood mononuclear cells after a positive selection using MACS "TCR γ/δ + T cell isolation kit"

Journal of Immunological Methods

Volumn 347, Issue 1-2, 2009, Pages 12-18

  Salot, Samuel ^a   Bercegeay, Sylvain ^b   Dreno, Brigitte ^b   Saïagh, Soraya ^b   Scaglione, Virginie ^a   Bonnafous, Cécile ^a   Sicard, Hélène ^a  

^a INNATE PHARMA   (France)

^b INSTITUT DE BIOLOGIE   (France)

Author keywords

T lymphocytes; Cell therapy; Ex vivo expansion; Immunotherapy; Innate immunity; Phosphoantigen

Indexed keywords

GAMMA INTERFERON; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1;

ARTICLE; CELL EXPANSION; CELL ISOLATION; CELL SELECTION; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DAUDI CELL; HUMAN; HUMAN CELL; LYMPHOMA CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RAJI CELL; T LYMPHOCYTE;

ANIMALS; BURKITT LYMPHOMA; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOMAGNETIC SEPARATION; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED NOD; MICE, SCID; PHOSPHOPROTEINS; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTE SUBSETS; TIME FACTORS;

EID: 67650504357     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2009.05.006     Document Type: Article

References (27)

1. Bank I., Book M., Huszar M., Baram Y., Schnirer I., and Brenner H. V delta 2+gamma delta T lymphocytes are cytotoxic to the MCF 7 breast carcinoma cell line and can be detected among the T cells that infiltrate breast tumors. Clin. Immunol. Immunopathol. 67 (1993) 17
2. Bennouna J., Bompas E., Neidhardt E.M., Rolland F., Philip I., Galéa C., Salot S., Saiagh S., Audrain M., Rimbert M., Lafaye-de Micheaux S., Tiollier J., and Négrier S. Phase-I study of Innacell gammadeltatrade mark, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer Immunol. Immunother. 57 (2008) 599
3. Bouet-Toussaint F., Cabillic F., Toutirais O., Le Gallo M., Thomas de la Pintière C., Daniel P., Genetet N., Meunier B., Dupont-Bierre E., Boudjema K., and Catros V. Vgamma9Vdelta2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas. Cancer Immunol. Immunother. 57 (2008) 531
4. Brenner M.B., McLean J., Scheft H., Riberdy J., Ang S.L., Seidman J.G., Devlin P., and Krangel M.S. Two forms of the T-cell receptor gamma protein found on peripheral blood cytotoxic T lymphocytes. Nature 325 (1987) 689
5. Bukowski J.F., Morita C.T., Tanaka Y., Bloom B.R., Brenner M.B., and Band H. V gamma 2 V delta 2 TCR-dependent recognition of non-peptide antigens and Daudi cells analyzed by TCR gene transfer. J. Immunol. 154 (1995) 998
6. Burjanadzé M., Condomines M., Reme T., Quittet P., Latry P., Lugagne C., Romagne F., Morel Y., Rossi J.F., Klein B., and Lu Z.Y. In vitro expansion of gamma delta T cells with anti-myeloma cell activity by Phosphostim and IL-2 in patients with multiple myeloma. Br. J. Haematol. 139 (2007) 206
7. Constant P., Davodeau F., Peyrat M.A., Poquet Y., Puzo G., Bonneville M., and Fournie J.J. Stimulation of human gamma delta T cells by nonpeptidic mycobacterial ligands. Science 264 (1994) 267
8. Corvaisier M., Moreau-Aubry A., Diez E., Bennouna J., Mosnier J.F., Scotet E., Bonneville M., and Jotereau F. V gamma 9V delta 2 T cell response to colon carcinoma cells. J. Immunol. 175 (2005) 5481
9. Ferrarini M., Heltai S., Pupa S.M., Mernard S., and Zocchi R. Killing of laminin receptor-positive human lung cancers by tumor infiltrating lymphocytes bearing gammadelta(+) T-cell receptors. J. Natl. Cancer Inst. 88 (1996) 436
10. Fisch P., Meuer E., Pende D., Rothenfusser S., Viale O., Kock S., Ferrone S., Fradelizi D., Klein G., Moretta L., Rammensee H.G., Boon T., Coulie P., and van der Bruggen P. Control of B cell lymphoma recognition via natural killer inhibitory receptors implies a role for human Vgamma9/Vdelta2 T cells in tumor immunity. Eur. J. Immunol. 27 (1997) 3368
11. Fujimiya Y., Suzuki Y., Katakura R., Miyagi T., Yamaguchi T., Yoshimoto T., and Ebina T. In vitro interleukin 12 activation of peripheral blood CD3(+)CD56(+) and CD3(+)CD56(-) gammadelta T cells from glioblastoma patients. Clin. Cancer Res. 3 (1997) 633
12. Hwang L.N., Yu Z., Palmer D.C., and Restifo N.P. The in vivo expansion rate of properly stimulated transferred CD8+ T cells exceeds that of an aggressively growing mouse tumor. Cancer Res. 15 (2006) 1132
13. Kaur I., De Jong J., Schell K., Hank J., Fisch P., and Sondel P.M. Human peripheral gamma delta T cells are stimulated by Daudi Burkitt's lymphoma and not by any other Burkitt's lymphoma tested. Cell. Immunol. 156 (1994) 54
14. Klebanoff C.A., Gattinoni L., and Restifo N.P. CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol. Rev. 211 (2006) 214
15. Kobayashi H., Tanaka Y., Yagi J., Toma H., and Uchiyama T. Gamma/delta T cells provide innate immunity against renal cell carcinoma. Cancer Immunol. Immunother. 50 (2001) 115
16. Kroca M., Johansson A., Sjostedt A., and Tarnvik A. V gamma 9V delta 2 T cells in human legionellosis. Clin. Diagn. Lab. Immunol. 8 (2001) 949
17. Lopez R.D., Xu S., Guo B., Negrin R.S., and Waller E.K. CD2-mediated IL-12-dependent signals render human gamma delta-T cells resistant to mitogen-induced apoptosis, permitting the large-scale ex vivo expansion of functionally distinct lymphocytes: implications for the development of adoptive immunotherapy strategies. Blood 96 (2000) 3827
18. Malkovska V., Cigel F.K., Armstrong N., Storer B.E., and Hong R. Antilymphoma activity of human gamma delta T-cells in mice with severe combined immune deficiency. Cancer Res. 52 (1992) 5610
19. Mitropoulos D., Kooi S., Rodriguez-Villanueva J., and Platsoucas C.D. Characterization of fresh (uncultured) tumour-infiltrating lymphocytes (TIL) and TIL-derived T cell lines from patients with renal cell carcinoma. Clin. Exp. Immunol. 97 (1994) 321
20. Otto M., Barfield R.C., Martin W.J., Iyengar R., Leung W., Leimig T., Chaleff S., Gillies S.D., and Handgretinger R. Combination immunotherapy with clinical-scale enriched human gammadelta T cells, hu14.18 antibody, and the immunocytokine Fc-IL7 in disseminated neuroblastoma. Clin. Cancer Res. 11 (2005) 8486
21. Parker C.M., Groh V., Band H., Porcelli S.A., Morita C., Fabbi M., Glass D., Strominger J.L., and Brenner M.B. Evidence for extrathymic changes in the T cell receptor gamma/delta repertoire. J. Exp. Med. 171 (1990) 1597
22. Poupot M., and Fournie J.J. Non-peptide antigens activating human Vgamma9/Vdelta2 T lymphocytes. Immunol. Lett. 95 (2004) 129
23. Salot S., Laplace C., Saïagh S., Bercegeay S., Tenaud I., Cassidanius A., Romagne F., Dreno B., and Tiollier J. Large scale expansion of gamma 9 delta 2 T lymphocytes: Innacell gamma delta cell therapy product. J. Immunol. Methods 326 (2007) 63
24. Sturm E., Braakman E., Fisch P., Vreugdenhil R.J., Sondel P., and Bolhuis R.L. Human V gamma 9-V delta 2 T cell receptor-gamma delta lymphocytes show specificity to Daudi Burkitt's lymphoma cells. J. Immunol. 145 (1990) 3202
25. Tanaka Y., Morita C.T., Tanaka Y., Nieves E., Brenner M.B., and Bloom B.R. Natural and synthetic non-peptide antigens recognized by human gamma delta T cells. Nature 375 (1995) 155
26. Walzer T., Dalod M., Vivier E., and Zitvogel L. Natural killer cell dendritic cell crosstalk in the initiation of immune responses. Expert Opin. Biol. Ther. Suppl. 1 (2005) S49
27. Zheng B.J., Chan K.W., Im S., Chua D., Sham J.S., Tin P.C., He Z.M., and Ng M.H. Anti-tumor effects of human peripheral gammadelta T cells in a mouse tumor model. Int. J. Cancer 92 (2001) 421